The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1272
ISSUE1272
October 22, 2007
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
October 22, 2007 (Issue: 1272)
Ambrisentan (Letairis - Gilead), a selective endothelin type A (ETA) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial hypertension (PAH).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.